Immunic is trading 6.1% lower at $10.18 after reversing an early premarket gain; the specific catalyst remains unclear.
- No new company-specific announcement was identified for September 23, 2026. Recent news includes planned multiple-sclerosis R&D activity and executive appointments, neither of which directly explains the decline.
- Biotech shares were broadly stronger premarket, while broader U.S. equities weakened during regular trading.